Study protocol: a randomised controlled trial of a theory-based online intervention to improve sun safety among Australian adults.

abstract：BACKGROUND:A substantial number of patients will develop further biochemical progression after radical prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-specific membrane antigen ligand positron emission tomography (PSMA - PET) for re-staging suggest that those recurrences are of...

journal_title：BMC cancer

authors： Oehus AK,Kroeze SGC,Schmidt-Hegemann NS,Vogel MME,Kirste S,Becker J,Burger IA,Derlin T,Bartenstein P,Eiber M,Mix M,la Fougère C,Belka C,Combs SE,Grosu AL,Müller AC,Guckenberger M,Christiansen H,Henkenberens C

更新日期：2020-04-29 00:00:00

abstract：BACKGROUND:The association between colorectal cancer (CRC) and smoking has not been consistent. Incomplete smoking history and association to a specific subset of CRC tumors have been proposed as explanations. The adenomatous polyposis coli (APC) gene has been reported to have a "gatekeeper" function in the colonic muc...

journal_title：BMC cancer

authors： Sarebø M,Skjelbred CF,Breistein R,Lothe IM,Hagen PC,Bock G,Hansteen IL,Kure EH

更新日期：2006-03-17 00:00:00

abstract：BACKGROUND:Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. Meta-analysis of single-arm studies shows the potential of neo-adjuvant chemo-radiotherapy but the rela...

journal_title：BMC cancer

authors： Holyoake DL,Ward E,Grose D,McIntosh D,Sebag-Montefiore D,Radhakrishna G,Patel N,Silva M,Mukherjee S,Strauss VY,Odondi L,Fokas E,Melcher A,Hawkins MA

更新日期：2016-09-13 00:00:00

abstract：BACKGROUND:This planning study compares different radiotherapy techniques for patients with pituitary adenoma, including flatness filter free mode (FFF), concerning plan quality and secondary malignancies for potentially young patients. The flatness filter has been described as main source of photon scatter. MATERIAL ...

journal_title：BMC cancer

authors： Treutwein M,Steger F,Loeschel R,Koelbl O,Dobler B

更新日期：2020-02-03 00:00:00

abstract：BACKGROUND:p53 (encoded by TP53) is involved in DNA damage repair, cell cycle regulation, apoptosis, aging and cellular senescence. TP53 is mutated in around 50% of human cancers. Nevertheless, the consequences of p53 inactivation in colon cancer outcome remain unclear. Recently, a new role of p53 together with CSNK1A1...

journal_title：BMC cancer

authors： Sarasqueta AF,Forte G,Corver WE,de Miranda NF,Ruano D,van Eijk R,Oosting J,Tollenaar RA,van Wezel T,Morreau H

更新日期：2013-06-05 00:00:00

abstract：BACKGROUND:Papillary carcinomas that measure 1.0cm or less are diagnosed as papillary thyroid microcarcinomas (PTMs). The clinical significance and recommendations for management of these PTMs is still evolving. The objective of the study was to compare the characteristics of small (<5mm) to large (≥ 5mm) papillary thy...

journal_title：BMC cancer

authors： Bradley NL,Wiseman SM

更新日期：2017-02-16 00:00:00

abstract：BACKGROUND:The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. This meta-analysis is performed to provide an assessment of whether expression variations of TS are associated with objec...

journal_title：BMC cancer

authors： Wang L,Wang R,Pan Y,Sun Y,Zhang J,Chen H

更新日期：2014-03-19 00:00:00

abstract：BACKGROUND:Muscle invasive bladder cancer (MIBC) is often lethal and non-MIBC (NMIBC) can recur and progress, yet prognostic markers are currently inadequate. SAM68, a member of RNA-binding proteins, has been reported to contribute to progression of other cancers. The aim of this study is to investigate the potential u...

journal_title：BMC cancer

authors： Zhang Z,Yu C,Li Y,Jiang L,Zhou F

更新日期：2015-05-06 00:00:00

abstract：BACKGROUND:Cancer cell repopulation during chemotherapy or radiotherapy is a major factor limiting the efficacy of treatment. Cancer stem cells (CSC) may play critical roles during this process. We aim to demonstrate the role of mesothelioma stem cells (MSC) in treatment failure and eventually to design specific target...

journal_title：BMC cancer

authors： Wu L,Blum W,Zhu CQ,Yun Z,Pecze L,Kohno M,Chan ML,Zhao Y,Felley-Bosco E,Schwaller B,de Perrot M

更新日期：2018-04-27 00:00:00

abstract：BACKGROUND:The increasing number of individuals living with cancer has led to a focus on the quality of life of survivors, and their families. Sexual wellbeing is a central component of quality of life, with a growing body of research demonstrating the association between cancer and changes to sexuality and intimacy. H...

journal_title：BMC cancer

authors： Perz J,Ussher JM,Gilbert E

更新日期：2013-05-31 00:00:00

abstract：BACKGROUND:Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation. We wanted to prospectively assess feasibility of systemic ant...

journal_title：BMC cancer

authors： Eilard MS,Andersson M,Naredi P,Geronymakis C,Lindnér P,Cahlin C,Bennet W,Rizell M

更新日期：2019-06-11 00:00:00

abstract：BACKGROUND:The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare. METHODS:We...

journal_title：BMC cancer

authors： Reithmeier T,Graf E,Piroth T,Trippel M,Pinsker MO,Nikkhah G

更新日期：2010-02-02 00:00:00

abstract：BACKGROUND:Associations between polycyclic aromatic hydrocarbons (PAHs) and colorectal cancer have been reported previously but few studies have characterized PAH exposure using biological measurements. We evaluated colorectal cancer risk in relation to urinary concentration of 1-hydroxypyrene glucuronide (1-OHPG), a p...

journal_title：BMC cancer

authors： Hofmann JN,Liao LM,Strickland PT,Shu XO,Yang G,Ji BT,Li HL,Rothman N,Kamangar F,Gao YT,Zheng W,Chow WH

更新日期：2013-06-11 00:00:00

abstract：BACKGROUND:Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug's survival benefits is challenging because clinical responses are rarely measurable during treatment. In this study, we hypothesized that...

journal_title：BMC cancer

authors： Hayashi T,Yamashita T,Terashima T,Suda T,Okada H,Asahina Y,Hayashi T,Hara Y,Nio K,Sunagozaka H,Takatori H,Arai K,Sakai Y,Yamashita T,Mizukoshi E,Honda M,Kaneko S

更新日期：2017-12-19 00:00:00

abstract：BACKGROUND:High invasion and metastasis are the primary factors causing poor prognosis of patients with hepatocellular carcinoma (HCC). However, the molecular mechanisms underlying these biological behaviors have not been completely elucidated. In this study, we investigate the molecular mechanism by which hypoxia prom...

journal_title：BMC cancer

authors： Zhang L,Huang G,Li X,Zhang Y,Jiang Y,Shen J,Liu J,Wang Q,Zhu J,Feng X,Dong J,Qian C

更新日期：2013-03-09 00:00:00

abstract：BACKGROUND:Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side e...

journal_title：BMC cancer

authors： Schneider TC,Kapiteijn E,van Wezel T,Smit JWA,van der Hoeven JJM,Morreau H

更新日期：2016-01-19 00:00:00

abstract：BACKGROUND:Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma (HCC). One potential target is the Src family Kinase (SFK). C-Src, a non-receptor tyrosine kinase is a critical link of multiple signal pathways that regulate proliferation, invasion, survival, metastasis, and angioge...

journal_title：BMC cancer

authors： Chang AY,Wang M

更新日期：2013-05-30 00:00:00

abstract：BACKGROUND:Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of GBM cells to TMZ is affected by many factors. And, several clinic trials, including co-administration...

journal_title：BMC cancer

authors： Li L,Huang Y,Gao Y,Shi T,Xu Y,Li H,Hyytiäinen M,Keski-Oja J,Jiang Q,Hu Y,Du Z

更新日期：2018-12-04 00:00:00

abstract：BACKGROUND:The aim of the trial was to compare two active adjuvant chemotherapy regimens in patients with early stage colorectal cancer (CRC). METHODS:Patients were assigned to oxaliplatin, leucovorin and 5-FU for 12 cycles (group A, FOLFOX6) or oxaliplatin and capecitabine for eight cycles (group B, CAPOX). Primary e...

journal_title：BMC cancer

authors： Pectasides D,Karavasilis V,Papaxoinis G,Gourgioti G,Makatsoris T,Raptou G,Vrettou E,Sgouros J,Samantas E,Basdanis G,Papakostas P,Bafaloukos D,Kotoula V,Kalofonos HP,Scopa CD,Pentheroudakis G,Fountzilas G

更新日期：2015-05-10 00:00:00

abstract：BACKGROUND:Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investig...

journal_title：BMC cancer

authors： Deng L,Ren Z,Jia Q,Wu W,Shen H,Wang Y

更新日期：2013-07-29 00:00:00

abstract：BACKGROUND:Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short intervals. We investigated the optimal metronomic dose of oral vinorelbine when given as monotherapy in patients with metastatic cancer. METHODS:Patients with recur...

journal_title：BMC cancer

authors： Briasoulis E,Aravantinos G,Kouvatseas G,Pappas P,Biziota E,Sainis I,Makatsoris T,Varthalitis I,Xanthakis I,Vassias A,Klouvas G,Boukovinas I,Fountzilas G,Syrigos KN,Kalofonos H,Samantas E

更新日期：2013-05-29 00:00:00

abstract：BACKGROUND:The discovery of a solitary pulmonary nodule (SPN) on a chest imaging exam is of major clinical concern. However, the incidence rates of SPNs in a general population have not been estimated. The objective of this study was to provide incidence estimates of SPNs in a general population in 5 northeastern regio...

journal_title：BMC cancer

authors： Marrer É,Jolly D,Arveux P,Lejeune C,Woronoff-Lemsi MC,Jégu J,Guillemin F,Velten M

更新日期：2017-01-11 00:00:00

abstract：BACKGROUND:We analyzed the influence of 8 germinal polymorphisms of candidate genes potentially related to EGFR signalling (EGFR, EGF, CCND1) or antibody-directed cell cytotoxicity (FCGR2A and FCGR3A) on outcome of colorectal cancer (CRC) patients receiving cetuximab-based therapy. METHODS:Fifty-eight advanced CRC pat...

journal_title：BMC cancer

authors： Dahan L,Norguet E,Etienne-Grimaldi MC,Formento JL,Gasmi M,Nanni I,Gaudart J,Garcia S,Ouafik L,Seitz JF,Milano G

更新日期：2011-11-25 00:00:00

abstract：BACKGROUND:Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late toxicities of pelvic radiation. Major tumour regression following pCRT has stro...

journal_title：BMC cancer

authors： Jameson MB,Gormly K,Espinoza D,Hague W,Asghari G,Jeffery GM,Price TJ,Karapetis CS,Arendse M,Armstrong J,Childs J,Frizelle FA,Ngan S,Stevenson A,Oostendorp M,Ackland SP

更新日期：2019-12-17 00:00:00

abstract：BACKGROUND:First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPI...

journal_title：BMC cancer

authors： Miyo M,Kato T,Yoshino T,Yamanaka T,Bando H,Satake H,Yamazaki K,Taniguchi H,Oki E,Kotaka M,Oba K,Miyata Y,Muro K,Komatsu Y,Baba H,Tsuji A

更新日期：2020-07-23 00:00:00

abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is a type of breast cancer with a high degree of malignancy. Because of the remarkable biological characteristics of high invasion, metastasis and recurrence, TNBC is often accompanied by a poor prognosis. As a molecular characteristic of TNBC, high expression of CD147 ha...

journal_title：BMC cancer

authors： Wang C,Xu C,Niu R,Hu G,Gu Z,Zhuang Z

更新日期：2019-06-13 00:00:00

abstract：BACKGROUND:The incidence of papillary thyroid cancer (PTC) is markedly higher in women than men during the reproductive years. In vitro studies have suggested that estrogen may play an important role in the development and progression of PTC through estrogen receptors (ERs). This study aimed to investigate the expressi...

journal_title：BMC cancer

authors： Huang Y,Dong W,Li J,Zhang H,Shan Z,Teng W

更新日期：2014-05-29 00:00:00

abstract：BACKGROUND:The aim of the study was to investigate whether p503S, p504S and p510S gene expression in peripheral-blood be useful as a diagnostic or prognostic marker of prostatic cancer. METHODS:Circulating cells were identified by reverse transcription-polymerase chain reaction (RT-PCR) to detect p503S, p504S and p510...

journal_title：BMC cancer

authors： Cardillo MR,Gentile V,Ceccariello A,Giacomelli L,Messinetti S,Di Silverio F

更新日期：2005-09-05 00:00:00

abstract：BACKGROUND:Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overall survival is still onl...

journal_title：BMC cancer

authors： Combs SE,Kieser M,Rieken S,Habermehl D,Jäkel O,Haberer T,Nikoghosyan A,Haselmann R,Unterberg A,Wick W,Debus J

更新日期：2010-09-06 00:00:00

abstract：BACKGROUND:Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was ...

journal_title：BMC cancer

authors： Kakizoe M,Yao M,Tateishi U,Minamimoto R,Ueno D,Namura K,Makiyama K,Hayashi N,Sano F,Kishida T,Kobayashi K,Noguchi S,Ikeda I,Ohgo Y,Taguri M,Morita S,Inoue T,Kubota Y,Nakaigawa N

更新日期：2014-06-02 00:00:00